1597-Immune Predictors of Radioimmunotherapy Response
This paper details the RAPPORT trial, a clinical study investigating the efficacy of combining stereotactic ablative body radiotherapy (SABR) with the immunotherapy drug pembrolizumab to treat metastatic kidney cancer. Researchers performed deep immune profiling on patient tumors and blood samples to identify biological markers that determine why some patients respond to this dual treatment while others do not. The study found that successful outcomes are linked to high baseline levels of cytotoxic T cells positioned in close proximity to cancer cells. Conversely, patients who did not benefit…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.